Logo

Coherus Reports the US FDA's Acceptance of BLA for CHS-1420 (biosimilar- adalimumab)

Share this
Coherus Reports the US FDA's Acceptance of BLA for CHS-1420 (biosimilar- adalimumab)

Coherus Reports the US FDA's Acceptance of BLA for CHS-1420 (biosimilar- adalimumab)

Shots:

  • The US FDA has accepted the BLA under the 351(k) for CHS-1420 with an anticipated BsUFA date as Dec’2021
  • The company plans to launch the CHS-1420 in the US on or after Jul 01- 2023 as per the terms of an agreement with AbbVie
  • Coherus collaborated with Junshi in Feb’2021 to in-license toripalimab in the US and Canada. Additionally- Coherus will market Udenyca (pegfilgrastim) in the US and plans to launch biosimilars of Humira- Avastin and Lucentis in 2023- following their approval

 ­ Ref: GlobeNewswire | Image: Coherus

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions